Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751398 | 1.00 | KDM4E (0.40) | KDM4EHTTTDP1MAPTALDH1A1 | |
| SCHEMBL2306361 | 1.00 | KDM4E (0.40) | KDM4EHTTTDP1MAPTALDH1A1 | |
| SCHEMBL2310406 | 0.86 | KDM4E (0.42) | KDM4EHTTTDP1MAPTALDH1A1 | |
| SCHEMBL17451277 | 0.77 | KDM4E (0.36) | KDM4EHTTTDP1MAPTALDH1A1 | |
| SCHEMBL2306871 | 0.75 | TSHR (0.41) | KDM4EHTTMAPTALDH1A1KMT2A | |
| SCHEMBL5014273 | 0.75 | TSHR (0.41) | KDM4EHTTMAPTALDH1A1KMT2A | |
| SCHEMBL2305986 | 0.75 | TSHR (0.41) | KDM4EHTTMAPTALDH1A1KMT2A | |
| SCHEMBL5011006 | 0.74 | KDM4E (0.39) | KDM4EHTTTDP1MAPTALDH1A1 | |
| SCHEMBL5014297 | 0.74 | KDM4E (0.36) | KDM4EHTTTDP1MAPTALDH1A1 | |
| SCHEMBL3069796 | 0.74 | KDM4E (0.38) | KDM4EHTTTDP1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350077-B1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS LTD (GB) | 2016-01-27 | — | — | EP | disclosed |
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | ENTASIS THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-9040528-B2 | Chemical compounds 542 | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | ASTRAZENECA AB (SE) | 2014-05-08 | — | — | US | disclosed |
| US-8658641-B2 | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2014-02-25 | — | — | US | disclosed |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| EP-2350077-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100261719-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| EP-2193132-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010043893-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009004382-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368266-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | KDM4E 4091/4885HTT 3817/4885TDP1 4670/4885 |
| US-20110245224-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | SDHB, SDHA, RORC | KDM4E 4677/4885HTT 4044/4885TDP1 4633/4885 |
| US-20100261719-A1 | CHEMICAL COMPOUNDS | NCOA3, NR4A3, NR0B2 | KDM4E 4486/4885HTT 2271/4885TDP1 4484/4885 |
| US-20140128371-A1 | CHEMICAL COMPOUNDS 542 | MRPL21, CFTR, CYP3A43 | KDM4E 4091/4885HTT 3817/4885TDP1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.